Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...

Related Keywords

Germany ,Denmark ,Copenhagen ,Køavn ,Japan ,Chicago ,Illinois ,United States ,America ,American ,Judith Klimovsky ,Fosun Pharma ,David Freundel ,Andrew Carlsen ,Asia Pacific ,Exchange Commission ,Pfizer ,American Society Of Clinical Oncology ,American Cancer Society ,Roche Group ,Genentech ,Clinical Oncology ,Annual Meeting ,Executive Vice President ,Chief Development Officer ,Chief Medical Officer ,Non Small Cell Lung Cancer ,North America ,Media Release ,Annual Report ,Y Shaped Genmab ,New Technologies ,Private Securities Litigation Reform Act ,American Cancer ,Non Small Cell Lung ,Lung Cancer ,Non Small Cell ,